Is there a Bearish outlook for Eleven Biotherapeutics Inc (NASDAQ:EBIO) this week?

July 17, 2017 - By Vivian Park

 Is there a Bearish outlook for Eleven Biotherapeutics Inc (NASDAQ:EBIO) this week?
Investors sentiment decreased to 1 in 2016 Q4. Its down 1.29, from 2.29 in 2016Q3. It worsened, as 6 investors sold Eleven Biotherapeutics Inc shares while 5 reduced holdings. 5 funds opened positions while 6 raised stakes. 1.14 million shares or 22.20% more from 933,766 shares in 2016Q3 were reported.
Northern Trust holds 0% or 17,976 shares. The New York-based Spark Mgmt Ltd Liability has invested 0.02% in Eleven Biotherapeutics Inc (NASDAQ:EBIO). Bank Of Ny Mellon reported 40,358 shares. Fiduciary Trust reported 10,000 shares. Vanguard reported 0% stake. Barclays Public Limited Co reported 13 shares. Eagle Glob Advisors Ltd Llc holds 0% of its portfolio in Eleven Biotherapeutics Inc (NASDAQ:EBIO) for 21,602 shares. Citigroup reported 500 shares or 0% of all its holdings. Susquehanna Int Gru Limited Liability Partnership stated it has 0% of its portfolio in Eleven Biotherapeutics Inc (NASDAQ:EBIO). Royal Bancorporation Of Canada has invested 0% in Eleven Biotherapeutics Inc (NASDAQ:EBIO). Blackrock Fund Advsrs stated it has 2,365 shares. Airain Limited invested 0% in Eleven Biotherapeutics Inc (NASDAQ:EBIO). Blackrock Institutional Tru Commerce Na stated it has 0% of its portfolio in Eleven Biotherapeutics Inc (NASDAQ:EBIO). Morgan Stanley stated it has 4,080 shares. Credit Suisse Ag holds 14,860 shares or 0% of its portfolio.

Eleven Biotherapeutics Inc (NASDAQ:EBIO) Ratings Coverage

Among 2 analysts covering Eleven Biotherapeutics (NASDAQ:EBIO), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Eleven Biotherapeutics had 4 analyst reports since August 15, 2015 according to SRatingsIntel. The stock of Eleven Biotherapeutics Inc (NASDAQ:EBIO) earned “Market Perform” rating by Leerink Swann on Tuesday, January 19. The firm has “Neutral” rating given on Wednesday, March 16 by Citigroup. The rating was maintained by Leerink Swann on Saturday, August 15 with “Outperform”. The firm has “Neutral” rating by Citigroup given on Tuesday, January 19. Below is a list of Eleven Biotherapeutics Inc (NASDAQ:EBIO) latest ratings and price target changes.

About 272,504 shares traded or 27.38% up from the average. Eleven Biotherapeutics Inc (NASDAQ:EBIO) has risen 30.97% since July 17, 2016 and is uptrending. It has outperformed by 14.27% the S&P500.

Eleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company. The company has market cap of $39.27 million. The Firm applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. It has a 8.28 P/E ratio. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema and uveitis.

More notable recent Eleven Biotherapeutics Inc (NASDAQ:EBIO) news were published by: Seekingalpha.com which released: “Eleven Biotherapeutics’ (EBIO) CEO Stephen Hurly on Q4 2016 Results – Earnings …” on March 24, 2017, also Seekingalpha.com with their article: “Eleven Biotherapeutics: No Immediate Pipeline And Running Out Of Cash; 70 …” published on May 06, 2016, Marketwatch.com published: “Eleven Biotherapeutics stock up 25% on news of Viventia Bio purchase” on September 21, 2016. More interesting news about Eleven Biotherapeutics Inc (NASDAQ:EBIO) were released by: Bostonglobe.com and their article: “Eleven Biotherapeutics buys Canadian company” published on September 21, 2016 as well as Seekingalpha.com‘s news article titled: “Eleven Bio: Is It Cheap?” with publication date: December 29, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.